Coherus Oncology (CHRS) Invested Capital (2014 - 2023)

Coherus Oncology (CHRS) posted Invested Capital of $3.3 million for Q4 2023, down 18.32% sequentially from $4.0 million in Q3 2023.

Coherus Oncology (CHRS) Invested Capital (2014 - 2023) Analysis & Trends

Coherus Oncology has reported Invested Capital for 6 years, with the latest figure at $3.3 million in Q4 2023.

Quarterly Invested Capital changed N/A year-over-year to $3.3 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $3.3 million (down 18.32% YoY) and the FY2023 annual result came in at $3.3 million, changed N/A from the prior year.
Invested Capital declined to $3.3 million in Q4 2023 per CHRS's latest filing, from $4.0 million in the prior quarter.
Over five years, Invested Capital peaked at $17.3 million in Q3 2021 and troughed at $3.3 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	190.90 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.45 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	380.00 Mn
10	Coherus Oncology	221.39 Mn	116.08 Mn	10.07 Mn	-

Download Data